About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Major Depressive Disorder Study In Adults

NCT00049972·71 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

GlaxoSmithKline

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patient must have primary diagnosis of Major Depressive Disorder (MDD).
Discontinued a selective serotonin reuptake inhibitor (SSRI)or serotonin-norepinephrine reuptake inhibitor (SNRI) regimen due to intolerability.
Minimum time frame between last dose of previous antidepressant and initiation of study drug is one week.
Maximum time frame between last dose of prior antidepressant and initiation of study drug is 2 months.

You may not be if

Patient has previously been treated with the study drug.
Is experiencing an adverse event attributed to previous SSRI/SNRI use that has not been resolved at least one week prior to Baseline Visit.
Has a history of seizure disorder.
Has met criteria for substance abuse or dependence within 6 months prior to Baseline Visit.
Currently using an antidepressant.
Currently pregnant.

The record

StatusCompleted

PhasePhase 4

Taking part646

StartedSep 2002

UpdatedSep 11, 2017

Conditions

Major Depressive Disorder

Where71

GSK Clinical Trial Call Center
Birmingham, Alabama, United States
GSK Clinical Trial Call Center
Birmingham, Alabama, United States
GSK Clinical Trial Call Center
Fairfield, Alabama, United States

Clareo Health | Major Depressive Disorder Study In Adults